Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 8 Nov 2026
Standard addition

Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.

Anti-PD-1 immunotherapy combined with chemotherapy shows the strongest evidence as a first-line treatment for advanced gastric cancers lacking HER2.

This PubMed-indexed study examined comparative efficacy and safety of first-line therapies for advanced her2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. Within the trial populations represented in this network, anti-PD-1 therapy plus doublet chemotherapy is the best-supported first-line chemoimmunotherapy strategy The analysis cannot determine CPS-specific effects, and favorable ACT rankings require confirmation before clinical application.

What the study was

Study design
Systematic review and network meta-analysis
Population
Human participants or human evidence described in the PubMed abstract
Sample size
347
Category
Treatment Innovation
Maturity
Validated
Journal
Critical reviews in oncology/hematology

Why it surfaced

Systematic review and network meta-analysis with PubMed abstract evidence; scored conservatively for treatment innovation relevance and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.